LYEL Stock Forecast: Lyell Immunopharma, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Lyell Immunopharma, Inc. hold a median 12-month price target of $39 — +182.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 80 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Lyell Immunopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (32): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LYEL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LYEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +182.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $45 → $39 |
| 3 Nov 2026 | Needham | Reiterates | Buy | $44 |
| 11 Sept 2026 | Needham | Reiterates | Buy | $44 |
| 6 Aug 2026 | Stifel | Initiates | Buy | $36 |
| 22 July 2026 | B. Riley Securities | Initiates | Buy | $44 |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | $34 |
| 15 June 2026 | Needham | Reiterates | Buy | $44 |
| 9 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $45 |
| 8 June 2026 | Needham | Reiterates | Buy | $44 |
| 3 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 May 2026 | Needham | Reiterates | Buy | — |
| 10 Apr 2026 | Needham | Initiates | Buy | — |
| 9 Mar 2026 | Citizens | Initiates | Market Outperform | — |
| 9 Dec 2025 | HC Wainwright & Co. | Upgrade | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 26 Sept 2025 | LUCID CAPITAL MARKETS | Initiates | Buy | — |
| 24 June 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 16 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LYEL.
This page is one stock. Monday covers all of them.
LYEL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LYEL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Lyell Immunopharma, Inc. returned −20.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LYEL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 29219.7×
- Price / book
- 1.7×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 49% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −97.8%
- Return on assets
- −36.9%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Lyell Immunopharma, Inc. has a market value of $434.8M and an enterprise value of $201.1M.
Revenue in the twelve months to 30 June 2026: $27K. The latest quarter shrank 50.0% year on year.
Net income over the same four quarters: −$248.5M, a −920285.2% net margin.
Diluted earnings per share, trailing twelve months: −$11.77.
Free cash flow in the twelve months to 30 June 2026: −$134.0M.
Lyell Immunopharma, Inc. employs 161 people — $167.7 of revenue per employee.
Data provided by Twelve Data
LYEL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LYEL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Lyell Immunopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LYEL
What is the LYEL stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Lyell Immunopharma, Inc. have a median 12-month price target of $39, with estimates ranging from $12 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LYEL stock a buy right now?
Of the 8 analysts covering Lyell Immunopharma, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Lyell Immunopharma, Inc. 80 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LYEL?
As at 21 Nov 2026, Lyell Immunopharma, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).
Will LYEL stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +182.6% from the last close, and Ticker Nerd's factor model ranks Lyell Immunopharma, Inc. 80 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LYEL stock forecast for 2030?
No analyst covering Lyell Immunopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LYEL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $49 over the next 12 months.
How has LYEL stock performed over the past year?
Lyell Immunopharma, Inc. returned -20.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Lyell Immunopharma, Inc. do?
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company focused on developing next-generation CAR T-cell therapies for cancer. The company is advancing a pipeline of product candidates designed to improve T-cell performance by helping cells resist exhaustion, persist longer, and maintain stronger tumor-fighting activity in challenging cancer environments.
About Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company focused on developing next-generation CAR T-cell therapies for cancer. The company is advancing a pipeline of product candidates designed to improve T-cell performance by helping cells resist exhaustion, persist longer, and maintain stronger tumor-fighting activity in challenging cancer environments. Its current programs target both hematologic malignancies and solid tumors, with work spanning blood cancers such as large B-cell lymphoma and solid-tumor indications including colorectal cancer. Lyell Immunopharma combines genetic and epigenetic T-cell reprogramming technologies with manufacturing capabilities to support product development and clinical testing. Based in South San Francisco, California, the company plays a role in the broader immunotherapy market by focusing on engineered cell-based treatments intended to address major unmet needs in oncology.
CEO Dr. Lynn Seely M.D., Ph.D. · 161 employees · United States · https://www.lyell.com